Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968630 · ClinicalTrials.gov registry record · Phase 2
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00968630 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT00968630, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer). Studying samples of blood from HIV-positive patients with cancer in the laboratory may help doctors learn more about changes that occur in the immune system after stem cell transplant.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Leukapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-12-17 |
| Est. Completion | 2017-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968630
The ClinicalTrials.gov registry entry for NCT00968630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00968630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968630 about?
NCT00968630 is a clinical study titled "Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer". This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer). Studying samples of blood from HIV-positive patients with cancer in the laboratory may help doctors learn more about changes that...
What is the current status of trial NCT00968630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-12-17. Estimated completion is 2017-03-17.
What interventions are being tested in trial NCT00968630?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Leukapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT00968630?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.